Introduction: Malignant neoplasms of bones and articular cartilage (ICD-10 C40-C41) are rare cancers that predominantly affect young individuals and the elderly, often requiring complex and high-cost treatments. In Brazil, disparities in access to early diagnosis, specialized care, and adequate treatment across regions may influence disease outcomes and survival rates. Understanding the spatial and temporal distribution of these hospitalizations is essential for identifying healthcare inequalities and supporting public health planning within the Unified Health System (SUS). Objectives: To analyse the spatiotemporal distribution characteristics of the treatment for malignant neoplasms of bones and articular cartilage in Brazil from 2014 to 2024. Methods: This descriptive ecological study with a temporal series and quantitative nature has used data from the Hospital Information System of the Unified Health System (SIH/SUS) concerning the treatment of malignant neoplasms of bones and articular cartilage in Brazil between 2014 and 2024. The variables used included number of hospitalizations, region, state, year of occurrence, type of hospitalization (elective or urgent), average cost of hospitalization, and mortality. The descriptive analysis was performed using Microsoft Excel 2021. Results: From 2014 to 2024, a total of 131,272 hospitalizations for malignant neoplasms of bones and articular cartilage were recorded in Brazil, with the highest concentration in the Southeast region, accounting for 50,375 (38.3%) cases, and the lowest one in the North region, with 6,581 (5%). The state of São Paulo led in hospitalizations, with 30,177 (22.9%) cases. The year 2024 recorded the highest number of treatments, with 13,239 (10%) hospitalizations. Regarding the type of hospitalization, 61,760 (47%) were urgent, with 26,975 (43.6%) occurring in the Southeast region. The highest average hospitalization cost was R$2,109.07 in the Southeast, and the lowest was R$1,792.82 in the Midwest. In terms of mortality, 6,578 deaths from these neoplasms were registered in Brazil, with the majority in 2023, totaling 645 (9,8%) deaths. The total of deaths in the Southeast region was 2,746 (41.7%), while the Midwest presented 440 (6.7%) cases. Conclusion: The data highlights significant regional inequalities in Brazil’s management of malignant bone and cartilage neoplasms. The Southeast, home to the largest population and the highest hospitalization costs, also records the most deaths and urgent cases—indicating that greater financial resources are not translating into better outcomes. This suggests systemic inefficiencies, likely tied to delayed diagnoses and unequal access to early care. In contrast, the Midwest, with the lowest average costs and fewer deaths, points to potentially more effective healthcare delivery despite fewer resources. The North’s minimal hospitalization numbers raise concerns about underdiagnosis and restricted access. The peak in treatments in 2024 following the highest death count in 2023 may reflect delayed care from previous systemic stress, possibly linked to broader public health disruptions. Altogether, the findings underscore that equitable access and timely intervention are more decisive for outcomes than spending alone.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
